Brain Matters Research is looking for participants for a new study called T2 Protect AD, a research study on Alzheimer’s Disease.
While Brain Matters Research is based in Delray Beach and has an office in Stuart, this study also includes 40 medical and academic clinical sites across the country.
The treatment being tested on people with mild to moderate Alzheimer’s Disease is called troriluzole, a drug that affects the brain chemical glutamate, which is important for healthy brain function.
The drug may protect against, slow down and improve memory and thinking problems which increase as the disease progresses.
Alzheimer’s Disease is a progressive, degenerative neurologic disease. High glutamate levels in the brain can lead to brain cell dysfunction and disease, including Alzheimer’s disease. Troriluzole helps normalize glutamate levels in the brain.The drug is already a FDA-approved treatment for Amyotrophic Lateral Sclerosis (ALS).
“I have been doing Alzheimer’s research for the past 15 years,” founder and president of Brain Matters Research Dr. Mark Brody said. “This is all I do now. I am always looking for different mechanisms.”
He said the drug has been slightly altered from the way it is used to slow the progression of ALS to have less G.I. side effects.
“We are hoping this drug truly makes a difference in this illness,” he said. “We badly need symptomatic therapies for mild to moderate stages of Alzheimer’s disease, when memory and thinking problems interfere with daily life. What really excites me is that troriluzole has the potential to improve cognitive symptoms in people with Alzheimer’s disease.”
He said it is too soon in the study to know if the drug works. His patients have been involved in the study, which is in phase 2, for a little more than three months.
The overall goal is to slow down the progression of the disease, he said.
The study is sponsored by New Haven-based Biohaven Pharmaceutical Holding Company Ltd., and is coordinated by the Alzheimer’s Disease Cooperative Study (ADCS), a large clinical research consortium based at the University of California, San Diego.
The T2 Protect AD trial comes at a time when Alzheimer’s research is focused on earlier stages of the disease and there are not as many clinical trials for people already diagnosed with Alzheimer’s.
“Simply put, we need to identify more and better treatments for the millions of people already diagnosed with Alzheimer’s disease and the T2 Protect Study is designed for that population” he said.
Clinicians at the Brain Matters Research are now seeking eligible participants for the T2 Protect AD study. To enroll in T2 Protect AD, participants must be between age 50 and 85, diagnosed with mild-to-moderate Alzheimer’s disease, and already being treated with Alzheimer’s medications for at least three months. Participants must have a study partner who has regular contact with the clinical trial candidate and is able to attend study visits.
Participants have a 50/50 chance of receiving the treatment. If selected to participate, patients take one pill once a day for 48 weeks along with any other medication they are taking for Alzheimer’s disease.
Dr. Brody said there is no cost to participate in the study and they are actively seeking more patients.
For more information about participating in the T2 Protect AD study at Brain Matters Research, call 561-381-9060 or visit T2ProtectAD.